Update on rosacea pathogenesis and correlation with medical therapeutic agents

Cutis

Volumn 78, Issue 2, 2006, Pages 97-100

  Del Rosso, James Q ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; PATHOPHYSIOLOGY; REVIEW; ROSACEA;

HUMANS; ROSACEA;

EID: 33748950622     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Del Rosso JQ. A status report on medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
2. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol. 1989;69:419-423.
3. Powell FC. Rosacea. N Engl J Med. 2005;352:793-803.
4. Dahl MV. Pathogenesis of rosacea. Adv Dermatol. 2001;17:29-45.
5. Rebora A. The red face: rosacea. Clin Dermatol. 1993;11: 225-234.
6. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.
7. Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
8. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
9. Del Rosso JQ. Medical management of rosacea with topical agents: a thorough appraisal of available treatment options and recent advances. Cosmet Dermatol. August 2003;16:47-48, 51-52, 55, 60.
10. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5: 5-13.
11. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512.
12. Del Rosso J, Bikowski J. Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial results evaluating the effects of 40 mg doxycycline monohydrate controlled-release capsules in treatment of rosacea [abstract]. J Am Acad Dermatol. 2006;54(suppl):AB30.
13. Oztas MO, Balk M, Ogus E, et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003;28:188-192.
14. Wilkin JK. Rosacea: pathophysiology and treatment. Arch Dermatol. 1994;130:359-362.
15. Wilkin JK. Oral-thermal flushing in erythematotelangiectatic rosacea. J Invest Dermatol. 1991;76:15-18.
16. Sobye P. Aetiology and pathogenesis of rosacea. Acta Derm Venereol. 1950;30:137-158.
17. Neumann E, Frithz A. Capillaropathy and capillaroneogenesis in the pathogenesis of rosacea. Int J Dermatol. 1998;37:263-266.
18. Aroni K, Tsagroni E, Lazaris AC, et al. Rosacea: a clinicopathological approach. Dermatology. 2004;209:177-182.
19. Helm KF, Menz J, Gibson LE, et al. Clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol. 1991;25:1038-1043.
20. Jones D. Reactive oxygen species and rosacea. Cutis. 2004;74(suppl 3):17-20.
21. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA. 1996;93: 14014-14019.
22. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest. 1997;100:2417-2423.
23. Schmidt NF, Gans EH. Demodex and rosacea, I: the prevalence and numbers of Demodex mites in rosacea. Cosmet Dermatol 2004;17:497-502.
24. Schmidt NF, Gans EH. Demodex and rosacea, II: Demodex mites and rosacea inflammation. Cosmet Dermatol. 2004;17:575-578,580.
25. Forton F, Germaux MA, Brasseur T, et al. Democidosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. 2005;52:74-87.
26. Dirschka T, Tronnier H, Folster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
27. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
28. Dahl MV, Ross AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50:266-272.
29. Bonamigo RR, Bakos L, Edelweiss M, et al. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venereol. 2005;19:646-647.
30. Alfonso A, Sobrin L, Monroy D. Tear fluid gelatinase B activity correlates with IL-1 alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506-2512.
31. Ramelet AA, Perroulaz G. Rosacea: histopathologic study of 75 cases. Ann Dermatol Venereol. 1998;115:801-806.
32. Murphy G. Ultraviolet light and rosacea. Cutis. 2004;74(suppl 3):13-16.
33. Kurkcuoglu N, Alaybeyi F. Substance P immunoreactivity in rosacea. J Am Acad Dermatol. 1991;25:725-726.
34. McClellan KJ, Noble S. Topical metronidazole: a review of its use in rosacea. Am J Clin Dermatol. 2000;1:191-199.
35. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282:449-454.
36. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
37. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
38. Akamatsu H, Asada M, Komura J, et al. Effect of doxycycline on the generation of reactive oxygen species: a possible mechanism of action of acne therapy with doxycycline. Acta Derm Venereol. 1992;72:178-179.
39. Skidmore RA, Walker C, Kovach R, et al. Effects of a subantimicrobial dose of doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.